For Healthcare Professionals

For the treatment of relapsing forms of multiple sclerosis,

Discover Savings With Glatopa®

The AP-Rated*, Fully Substitutable Generic Equivalent to COPAXONE® (glatiramer acetate injection)1,2

Not an actual patient.
Not an actual patient.

For the treatment of relapsing forms of multiple sclerosis,

Discover Savings With Glatopa®

The AP-Rated*, Fully Substitutable Generic Equivalent to COPAXONE® (glatiramer acetate injection)1,2

 

The lowest-priced glatiramer acetate injection in the US with extensive commercial coverage

Glatopa has the lowest wholesale acquisition cost (WAC) of all glatiramer acetate injection medicines available to people living with MS in the US3

~75% reduction in glatiramer acetate injection therapy costs in the US since the introduction of Glatopa and other generic glatiramer acetate therapies3,†

~For nearly 84% of commercial lives, Glatopa has favorable or equal coverage to COPAXONE® (glatiramer acetate injection)4,‡

Learn more about Glatopa coverage and savings
 

The first FDA-approved, fully substitutable, AP-rated* generic glatiramer acetate1,2

Same indication, same active ingredient, same dosage strengths, and same route of administration as COPAXONE® (glatiramer acetate injection)1,2

Similar safety and efficacy profile as COPAXONE®2

 

*A, no known or suspected bioequivalence problems; P, injectable solution.
†From 2015-2020.
‡Source: Fingertip Formulary, September 2017 for the 20 mg/mL dose.

Indication

Glatopa® (glatiramer acetate injection) is a prescription medicine indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Important Safety Information

Glatopa® is contraindicated in patients with known hypersensitivity to glatiramer acetate or mannitol.

Approximately 16% of glatiramer acetate injection 20 mg/mL patients vs 4% of those on placebo, and approximately 2% of glatiramer acetate injection 40 mg/mL patients vs none on placebo experienced a constellation of symptoms that may occur immediately (within seconds to minutes, with the majority of symptoms observed within 1 hour) after injection and included at least 2 of the following: flushing, chest pain, palpitations, tachycardia, anxiety, dyspnea, throat constriction, and urticaria. These symptoms generally have their onset several months after the initiation of treatment, although they may occur earlier, and a given patient may experience 1 or several episodes of these symptoms. Typically, the symptoms were transient and self-limited and did not require treatment; however, there have been reports of patients with similar symptoms who received emergency medical care.

Transient chest pain was noted in 13% of glatiramer acetate injection 20 mg/mL patients vs 6% of placebo patients, and approximately 2% of glatiramer acetate injection 40 mg/mL patients vs 1% on placebo. While some episodes of chest pain occurred in the context of the immediate post-injection reaction described above, many did not. The temporal relationship of this chest pain to an injection was not always known. The pain transient, often unassociated with other symptoms, and appeared to have no clinical sequelae. Some patients experienced more than 1 such episode, and episodes usually began at least 1 month after the initiation of treatment.

At injection sites, localized lipoatrophy and, rarely, injection site skin necrosis may occur. Lipoatrophy may occur at various times after treatment onset (sometimes after several months) and is thought to be permanent. There is no known therapy for lipoatrophy.

Because glatiramer acetate can modify immune response, it may interfere with immune functions. For example, treatment with glatiramer acetate may interfere with recognition of foreign antigens in a way that would undermine the body’s tumor surveillance and its defenses against infection. There is no evidence that glatiramer acetate does this, but there has not been a systematic evaluation of this risk.

Cases of hepatic injury, some severe, including liver failure and hepatitis with jaundice, have been reported with Glatopa. Hepatic injury has occurred from days to years after initiating treatment with Glatopa. If signs or symptoms of liver dysfunction occur, consider discontinuation of Glatopa.

The most common adverse reactions with glatiramer acetate injection 20 mg/mL vs placebo were injection site reactions (ISRs), such as erythema (43% vs 10%); vasodilatation (20% vs 5%); rash (19% vs 11%); dyspnea (14% vs 4%); and chest pain (13% vs 6%). The most common adverse reactions with glatiramer acetate injection 40 mg/mL vs placebo were ISRs, such as erythema (22% vs 2%).

ISRs were one of the most common adverse reactions leading to discontinuation of glatiramer acetate injection. ISRs, such as erythema, pain, pruritus, mass, edema, hypersensitivity, fibrosis, and atrophy, occurred at a higher rate with glatiramer acetate than placebo.

To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for Glatopa.

References

  1. Glatopa Prescribing Information. Sandoz Inc. July 2020.
  2. US Department of Health and Human Services. Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/media/71474/download. Accessed December 1, 2021.
  3. Data on File. Red Book. Sandoz Inc. January 2022.
  4. Data on file. Fingertip Formulary. Sandoz Inc. April 2019.